Incyte (INCY)
(Delayed Data from NSDQ)
$83.38 USD
+1.04 (1.26%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $83.39 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
INCY 83.38 +1.04(1.26%)
Will INCY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INCY
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
BMRN vs. INCY: Which Stock Is the Better Value Option?
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
Here's What Key Metrics Tell Us About Incyte (INCY) Q3 Earnings
Other News for INCY
Notable Wednesday Option Activity: INCY, PH, RCL
Merus: Petosemtamab Set Up For December 2024 Data Presentation
Bank of America Turns Bullish on These 2 Lesser-Known Stocks
Incyte Corp (INCY)'s Winning Formula: Financial Metrics and Competitive Strengths
Syndax, Royalty Pharma enter into $350M royalty funding deal